newsfilter
← Earnings
Earnings Releases·

MapLight Therapeutics — Third Quarter 2026 Earnings Summary

MapLight Therapeutics reported a net loss of $51.6 million for the third quarter of 2026, with cash, cash equivalents, and investments totaling $463.4 million as of September 30, 2026. The company has initiated start-up activities for the ZEPHYR-2 Phase 3 trial of its lead candidate ML-007C-MA in schizophrenia, with topline results expected in the second half of 2027. Enrollment is ongoing for the Phase 2 VISTA trial of ML-007C-MA in Alzheimer's disease psychosis, where the drug holds FDA Fast Track designation and top-line results are anticipated in 2028. Additionally, the company plans to engage with the FDA regarding the registrational path for ML-004 in autism spectrum disorder following positive Phase 2 IRIS trial data.

Company
MAPLIGHT THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology